💨 Abstract

A first-in-class, orally administered, non-hormonal male contraceptive pill named YCT-529, developed in the US, has moved to efficacy trials in humans after demonstrating safety in early-stage trials. It halts sperm production and is 99% effective in preclinical studies. The drug's effects are expected to become evident within weeks of administration.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖